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The Importance of Serum Procalcitonin Levels in
Patients with Chronic Obstructive Pulmonary Disease
Exacerbations
Aim: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable, but progressive disease
and hospital admissions of patients with COPD are frequently due to acute exacerbations. Acute phase
reactants are capable of demonstrating the inflammation; however, they cannot be employed to make a
difference between bacterial and nonbacterial causes of the inflammation. Recently, measurement of
procalcitonin (PCT) levels appears to be useful in order to minimize this problem. The aim of this study was
to examine whether the treatment arrangements based on serum PCT levels in patients presenting with COPD
acute exacerbations will be appropriate or not.
Materials and Methods: Nineteen patients with acute exacerbation of COPD and 16 patients with stable
COPD as the control group were enrolled in this study. Erythrocyte sedimentation rates (ESR) and complete
blood count (CBC) were obtained. Routine biochemical analysis and chest radiographs were examined in all
patients. All complaints of the patients were recorded and parameters (hemogram, ESR, serum procalcitonin,
hospital stay) were compared.
Results: Mean serum PCT levels in COPD patients with exacerbations was 1.8 ng/ml and in stable COPD
patients was 0.2 ng/ml. A significant correlation was established between serum procalcitonin (PCT) levels and
duration of hospital stay, ESR and sputum purulence (P = 0.002, P = 0.007 respectively). There was no
significant correlation between serum PCT levels, white blood cell count and complaints of patients.
Conclusions: We concluded that serum PCT measurements would be effective in guiding the treatment in
patients with acute exacerbations of COPD.
Key Words: Procalcitonin, COPD, acute exacerbation, acute phase reactants

Kronik Obstrüktif Akci¤er Hastal›¤› Alevlenmesinde
Serum Prokalsitonin Seviyesinin Önemi
Amaç: KOAH, önlenebilir, tedavi edilebilir ve ilerleyici bir hastal›k olmakla birlikte akut alevlenmeler nedeniyle
bu hastal›¤a yakalanm›ﬂ olanlar s›k s›k hastaneye baﬂvurmaktad›rlar. Akut faz reaktanlar› oluﬂan inflamasyonu
gösterebilmekte ancak bakteriyel-nonbakteriyel ay›r›m›n› yapamamaktad›r. Günümüzde prokalsitonin (PCT)
ölçümü ile bu sorun minimum seviyeye inmiﬂ görünmektedir. Bu çal›ﬂman›n amac› KOAH akut alevlenmesinde
serum PCT ölçümü ile tedavi planlanmas›n›n uygun olup olmayaca¤›n› araﬂt›rmakt›r.

Received: December 11, 2007
Accepted: February 12, 2008

Correspondence

Arzu BALKAN
Department of Pulmonary
Medicine,
Gülhane Military Medical Academy
06018 Etlik, Ankara - TURKEY
drabalkan@hotmail.com

Yöntem ve Gereç: Ondokuz KOAH alevlenmeli ve onalt› KOAH stabil hasta kontrol grubu olarak çal›ﬂmaya
al›nd›. Eritrosit sedimentasyon h›zlar› ve beyaz küreleri tesbit edildi. Tüm hastalar›n rutin biyokimyasal
analizleri yap›ld› ve PA akci¤er grafileri çektirildi. Çal›ﬂmaya al›nan hastalar›n ﬂikayetleri kay›t edilerek,
hemogram, sedimentasyon, serum prokalsitonin de¤erleri ve hastanedeki yat›ﬂ süreleri k›yasland›.
Bulgular: KOAH alevlenmesinde serum PCT ortalamas› 1,8 ng/ml, stabil KOAH hastalar›nda ise 0,2 ng/ml.
olarak ölçüldü. Hastalar›n serum prokalsitonin de¤erleri ile hastanede kal›ﬂ süresi, sedimentasyon ve balgam
pürülans› parametreleri aras›nda anlaml› korelasyon saptan›rken (s›ras›yla P = 0.002, P = 0.001, P = 0.007),
prokalsitonin de¤erleri ile beyaz küre düzeyleri ve klinik semptomlar aras›nda anlaml› iliﬂki saptanmad›.
Sonuç: Biz KOAH’l› hastalar›n akut alevlenmelerinde tedavi plan› içinde serum prokalsitonin düzeyi ölçümünün
etkili olabilece¤ini düﬂünmekteyiz.
Anahtar Sözcükler: Prokalsitonin, Kronik Obstrüktif Akci¤er Hastal›¤›, akut alevlenme, akut faz reaktanlar›
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
preventable as well as treatable disease that might also
have
extra-pulmonary
manifestations.
Airflow
obstruction is not completely reversible and generally
follows a progressive course. It is characterized by an
abnormal inflammatory response of the lungs against
harmful particles or gases (1).
COPD is a chronic inflammatory disease. It may cause
hospital admissions in those who do not receive regular
treatment or even in those who do as a result of
intervening pulmonary infections.
Many physiological changes occur in the host in order
to restore the impaired homeostasis during bacterial and
viral infections. These physiological changes are generally
known as the acute phase response and involve metabolic,
endocrinologic, neurologic and immunologic events.
Macrophages activated by the stimulation of the
infectious agent or its products initiate this acute phase
response via the cytokines (tumor necrosis factor-TNF,
interleukin-IL-1, IL-6) they release.
White blood cell (WBC) (leukocyte) count, absolute
neutrophil count, rod count and ratio, erythrocyte
sedimentation rate (ESR) and serum C-reactive protein
(CRP) levels are the most frequently used markers of
acute phase responses in clinical practice.
In patients with COPD, the clinical manifestations of
systemic infections due to infectious and non-infectious
causes are similar. The differential diagnosis of these two
conditions is very important in order to administer the
correct treatment regimen and avoid unnecessary
antibiotic use, thus reducing the morbidity, mortality and
care-related costs. The decision to use antibiotics and
selection of the type of antibiotic may be difficult in a
significant number of cases, primarily due to the
challenges encountered in confirming the diagnosis of
bacterial infections. Classical diagnostic instruments
including CRP and leukocyte count do not have sufficient
specificity in differentiating between bacterial infections,
non-infectious systemic inflammations or viral infections.
Therefore, more specific and reliable markers that might
be helpful in deciding the treatment are needed in these
patients.
140
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Recently, serum procalcitonin (PCT) has been used as
an infection marker (2-5). Since the extent and severity
of infection gradually increase in bacterial infections,
serum PCT levels have also been shown to increase. There
is even a specific cut-off value for PCT for the
establishment of a bacterial infection (6,7).
The aim of this study was to investigate whether the
measurement of PCT can be used in the differentiation of
bacterial and non-bacterial infection causes of COPD
exacerbation, thus helping in planning the treatment.

Materials and Methods
Nineteen COPD patients presenting with symptoms of
cough, sputum production, increased shortness of breath,
high fever or chest pain on the affected side were
considered to be experiencing acute exacerbations and
were included as the study group. Sixteen age- and sexmatched patients with stable COPD were included as the
control group. Approval of the hospital local ethics
committee was obtained and the investigators covered
the cost of the PCT kit.
COPD patients who received antibiotics before coming
to the outpatient clinic were excluded from the study.
Blood samples were collected from all patients in order to
perform complete blood count and routine biochemistry,
as well as to analyze acute phase reactants and serum
PCT. Direct inspection and culturing of the sputum
specimens that were obtained from patients with sputum
production were performed. Complaints of the patients
were recorded, posterior-anterior (PA) chest X-rays were
obtained and infiltrations, if any, were recorded. Duration
of hospital stay, sputum production and other complaints
such as pain on one side of the chest and high fever were
also recorded. Broad-spectrum antibiotics were started in
all patients displaying a possible bacterial etiology for the
exacerbations.
We concluded that serum PCT levels over 0.5 ng/ml
were valuable for bacterial infections.
The blood collected for serum PCT measurement was
centrifuged and kept at -80 °C until the time of the
measurement. PCT measurement was performed by the
Brahms
Diagnostica
device
using
the
immunoluminometric method with the inclusion of the
device’s own kit.
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purulent sputum, bacterial growth was shown in sputum
culture. The results were as follows: Gram-negative
bacillus in 1 patient, S. pneumoniae in 2 patients and H.
influenzae in 2 patients. In 12 out of 19 patients, serum
PCT was high, which supported bacterial infection. Seven
of 12 patients with high serum PCT levels had purulent
sputum. Eleven patients had one-sided chest pain. The
mean duration of hospital stay was 7 ± 3.2 days. Upon
assessment of the patients’ PA chest X-rays, 8 were found
to have infiltrations.

Parametric data were analyzed by the Spearman’s
correlation test and Pearson’s correlation test, and nonparametric data were analyzed by Mann-Whitney U test,
Fisher’s exact test and chi-square test.

Results
The mean age of the study group was 63 ± 5.2 years,
and included 4 females and 15 males. The mean age of
the control group with stable COPD was 56.3 ± 11.5
years, and included 5 females and 11 males. Demographic
characteristics of the patient and control groups are
shown in Table 1.

As expected, in the group presenting with COPD
exacerbation, high levels of WBC, serum PCT and ESR
were determined (Table 2).
We found significant correlations between serum PCT
levels and ESR, hospital stay, and purulence of sputum
(P = 0.002, P = 0.001, P = 0.007 respectively)
(Table 3).

Ten out of 19 patients in the study group had fever
≥38.0 °C, while the remaining 9 patients had normal
body temperature. Seven patients had purulent sputum
and 12 had a non-productive cough. In 5 of those with

Table 1. Demographic characteristics of the groups.
COPD Exacerbation
(n = 19)

Stable COPD Group
(n = 16)

Age (year)

63 ± 5.2

56.3 ± 11.5

Sex (M/F)

15/4

11/5

16 / 38 ± 6

12 / 42 ± 11

3/4

4/5

FVC (%)

82 ± 3.7

84 ± 4.6

FEV1 (%)

52 ± 10.4

58 ± 8.8

FEV1/FVC

61 ± 7.3

64 ± 6.1

Smoking history (n / pack-year)
Ex-smoker (n / year)

FVC: Forced vital capacity. FEV1: Forced expiratory volume in 1 second.

Table 2. Infection parameters in the study and control groups.
COPD Exacerbation
(n = 19)

Stable COPD Group
(n = 16)

P

12400 ± 4600

6200 ± 2800

0.002

PCT (ng/ml)

1.8 ± 0.8

0.2 ± 0.1

0.001

ESR (mm/h)

38 ± 17

8.1 ± 3.4

0.002

Duration of hospital stay (day)

7 ± 3.2

-

3
White Blood Cell (mm )

P < 0.05 statistically significant.
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Table 3. Correlation between clinical and laboratory findings.
Parameters

r

P

PCT

ESR

0.690

0.001

PCT

Purulent sputum

0.582

0.007

PCT

Infiltration

0.440

0.03

PCT

Duration of hospital stay

0.672

0.002

Purulent sputum

Infiltration

0.695

0.006

ESR

Infiltration

0.420

0.02

Body temperature

Infiltration

0.122

0.37

PCT

White blood cell

0.001

0.991

Chest pain

Infiltration

0.001

1.0

P < 0.05 statistically significant.

There was no statistically significant correlation
between the body temperature and infiltrations on chest
X-rays (P = 0.370), nor between chest pain and
infiltration (P = 1.00). The correlation between PCT
value and WBC count was also not significant (P =
0.991).

Discussion
Calcitonin, being the precursor of PCT, is secreted
from thyroid medullary cells and is related with calcium
metabolism (6). PCT is a protein having a molecular
weight of 13 kD and it consists of 116 amino acid
residues (7). The exact regions of its secretion are not yet
clear. Some literature suggests that PCT is secreted from
neuroendocrine cells of the liver, small intestine and
thyroid cells (6,8). In healthy humans, its normal serum
level is 0.1 ng/ml (6). In a previous study, administration
of bacterial endotoxin to healthy individuals resulted in an
increase in PCT levels starting two hours after
administration, with a peak value reached in 12 hours
(9). Consequently, the serum level remains constant for
another 12 hours and decreases back to normal level in
20-24 hours. PCT gives rapid response to bacterial
infections (4). Following the administration of bacterial
endotoxin, PCT levels increase faster and return to
normal range more rapidly compared to the levels of
CRP. Like PCT, the levels of acute phase reactants such as
IL-6 and TNF-alpha also increase rapidly in case of
infections (7). However, to assess the serum levels of
these reactants is difficult since regression to normal
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levels is also rapid. The means of elimination from serum
are not well defined; however, proteolysis by binding
blood proteins is a suggested mechanism (6,8). PCT is a
considerably stable molecule in laboratory conditions and
preserves its stability in repeated melting and freezing
conditions (8-10).
The sensitivity and specificity of PCT in bacterial
infections were found to be 92.6% and 97.5%,
respectively (11,12). In delayed bacterial infections (3-30
days), the sensitivity and specificity reached 100%.
Serum PCT level above 0.5 ng/ml indicates bacterial
infections, whereas levels above 2 ng/ml show sepsis (9).
When the threshold level of PCT indicative of bacterial
infection was accepted as 0.5 ng/ml, the positive and
negative predictive values were found to be 100% and
87%, respectively (11,12).
In this study, we have demonstrated that serum PCT
levels have high sensitivity and specificity in displaying the
inflammatory response in patients admitted with COPD
exacerbation. In the stable COPD patients that constituted
the control group, serum PCT levels were found to be
within normal limits.
Moreover, previous studies have shown that serum
PCT levels were increased generally in infections of
bacterial origin and this increase was more marked
especially in patients with septicemia (13-15). In the
literature, studies performed in patients with pneumonia
revealed that serum PCT levels have high sensitivity and
specificity in showing the inflammatory response caused
by pneumonia (16-19). It has also been suggested in
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some studies that serum PCT levels might have a
relatively higher sensitivity and specificity in
differentiating pneumonias of bacterial origin from those
of viral origin (20-23).

poorly significant relationship was found with the
infiltration observed in PA chest X-ray, suggesting that
infiltration does not necessarily always have a bacterial
etiology.

It has always been difficult to decide whether to start
antibiotics in patients admitted to outpatient clinics with
COPD exacerbations. Complaints of the patients
(increased coughing, increased sputum purulence,
increased shortness of breath, high fever), radiological
examinations, and laboratory measurements help
clinicians in this respect. PCT measurements, on the other
hand, may enable clinicians to distinguish bacterial
infections from non-bacterial ones and may make the
antibiotic decision easier with an increased confidence. In
general, this patient group does not have an isolated lung
problem and frequently has additional diseases such as
cardiac failure or coronary artery disease, and the
antibiotics to be administered have a narrow therapeutic
index. Studies have shown that the diagnostic efficacy of
leukocyte count is not high; it has either moderate or low
efficacy (15). In this study, we also were unable to find
any significant relationship between PCT and WBC count.
This suggests that WBC count is not a significant factor in
identifying a bacterial infection.

A significant correlation was found between the PCT
level and the duration of hospital stay, suggesting that
stable disease phase is achieved later in COPD
exacerbations of bacterial etiology. In 12 of 19 COPD
patients with acute exacerbations, the serum PCT levels
were higher than 0.5, and 7 patients had purulent
sputum. This suggests that COPD exacerbations with a
high PCT value may be a result of a bacterial infection
even if a bacterial growth is absent, and antibiotic use is
mandatory in these patients. Chang et al. (24) showed
that patients admitted with COPD exacerbation and
positive sputum cultures for bacterial pathogen had
significantly higher PCT values. A similar result was found
in another study of the same investigator performed in
August 2006 (25).

We found that PCT has a moderately significant
correlation with both ESR and purulent sputum. When
both of these parameters are used in combination with
the PCT value in identifying bacterial infection, the level
of significance is increased considerably. However, a

In another study, it was shown that PCT may be used
as a diagnostic tool in lower respiratory tract infections
and tuberculosis. In that study, PCT was measured high
in cases of COPD exacerbations caused by bacterial
infections (26). PCT measurements may also be used to
reveal the disease severity (27,28).
In conclusion, the results of this study suggest that
PCT may be used to guide the antibiotic therapy in COPD
exacerbations when the radiographic and clinical
parameters are not diagnostic.
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